MNPR
Monopar Therapeutics·NASDAQ
--
--(--)
--
--(--)
10.43 / 10
Outperform
Sentiment scores 10.43 (Outperform) and fund‑flow 7.89 (good), with positive inflows across all investor sizes. Analyst consensus is 100% Strong Buy from one BTIG analyst, historically 66.7% win rate and 12.97 weighted rating. Liquidity and analyst sentiment are strongly bullish.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-23
InstitutionBTIG
Times predicted6
Historical Win Rate66.7%
What is the analyst consensus for MNPR?
- MNPR holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 10.43/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
